SIMON, A.B., AND ZLOTO, A.E. Symptomatic sinus node disease: Natural history after permanent ventricular pacing. Fifty-nine patients between the ages of 13 and 88 with sinus node disease, who received a permanent ventricular pacemaker between 1965 and 1976 at one institution, were followed to determine the natural history of the disorder after permanent pacing. Nineteen had ischemic heart disease, six had primary myocardiaJ disease, and eight vaJvuJar heart disease. In 26, no etiology for the arrhythmia was apparent. The one-and five-year survival was 85,5% and 73,1%, respectively. Patients with underlying heart disease had a significantly poorer survival when compared to those without (58% versus 94% at 36 months], and all but 3 of 13 deaths in the first 36 months were in those with ischemic heart disease. There was a distinct trend toward poor survival in those with heart failure prior to pacemaker implant and those over age 65, Patients with sinus bradycardia alone did best (91% survival three years after implantj, while those with bradycardia-tachycardia syndrome and those with sinoatrial arrest alone did distinctly worse f76% and 65% survival at three years, respectively}. Twelve of 18 deaths were due to progression of underlying heart disease. The long-term prognosis with symptomatic sinus node disease can be predicted in part by (lj etiology of the underlying heart disease, [2} pre-implant arrhythmia, and (3J ventricular function prior to implant.
pathic, or ischemic heart disease, but many patients have no apparent etiology,*'' The course of untreated symptomatic sinus node disease is unknown, because permanent pacing was used for symptom palliation prior to the availability of natural history studies. Frequently, pacing must be combined with treatment of congestive failure or tachyarrhythmias for maximium palliation of symptoms."'' This report describes the natural history of symptomatic patients with sinus node disease who have received a ventricular pacemaker at one institution, and elucidates factors which correlate with late mortality and morbidity.
Methods

Patient Population
All adult patients who received their initial permanent pacemaker implantation for symptomatic sinus node disease at the University of Michigan Medical Center between July 1, 1965 and June 30, 1978 constitute the subjects of this report. Six patients with both sinus node dysfunction and atrioventricular block were excluded from this analysis and are described elsewhere.' Seven patients who had previously received their initial pacemaker elsewhere for this Indication but were subsequently followed here were also excluded. All patients were paced from the ventricle. The diagnosis of sinus node disease was made on clinical and electrocardiographic grounds''"'' and corroborated by electrophysiologic testing in some. The diagnosis for inclusion in this study in the patients paced prior to the description of the syndrome' was made retrospectively during a systematic evaluation of all patients receiving a permanent pacemaker in this institution.' Selected variables from the history, clinical course, sequential electrocardiograms, including Holter monitoring before and after pacemaker insertion, and follow-up information were transferred to computer tape and analyzed using methods previously described." All patients were assessed systematically at intervals no longer than six months. Special attention was paid to the atriai and underlying ventricular escape mechanism with pacemaker inhibition or at the time of pulse generator replacement. Survival curves were calculated according to the life table method using the Michigan Interactive Data Analysis System (MIDAS)" and the Interactive Graphic Survival Analysis System (IGSAS).'° Survival time for each patient extended from the date of initial pacemaker implant until death or June 30,1978. The Breslow's generalized Kruskal-Wallis Test was utilized to determine if the survival distribution differed across strata for any single pre-implant variable."
The etiology of the underlying heart disease and arrhythmias complex in each patient was classified according to clinical data at the time of initial pacemaker implant. Arteriosclerotic heart disease was accepted as etiologic only if the patient had a past history of definite angina pectoris, or ECG or enzyme evidence of prior myocardial infarction. Valvular heart disease or primary cardiomyopathy was diagnosed according to recognized clinical and catheterization critieria. Patients without apparent underlying cardiac disease were classified as 'idiopathic'. The method for the determination of the cause of death was similar to that previously described."'" When more than one etiology of heart disease was identified classification was according to the clinically dominant type at entry. Details concerning the circumstances of death were obtained by interview of physician, family member, or other informed witnesses. Sudden death was defined as death within one hour after the onset of symptoms. Congestive heart failure was diagnosed utilizing the criteria of McKee.'^ Chronic atriai fibrillation was defined as the presence of this arrhythmia on three successive electrocardiograms at least one year apart. During the time of the study, patients were paced from the ventricle at rates between 68 and 72 beats/minute with either General Electric,* Medtronic,** CPI*** or Corpacing systems. Table I . There were 19 patients with ischemic heart disease, of whom three also had hypertensive heart disease and four mitral insufficiency attributed to papillary muscle dysfunction. Six patients had primary myocardial disease, and eight had valvular disease. One of these has mitral valve prolapse with long QT syndrome, one isolated aortic stenosis, five rheumatic valve disease, and one patient has a tricuspid valve replacement secondary to endocarditis. Twenty-six patients had no apparent cardiac disease except the arrhythmia. Two patients in this latter group had quadriplegia or hemiplegia from spinal cord trauma. diabetes mellitus, 14 had systolic ( > 160 mm Hg) and 11 diastolic ( > 95 mm Hg) hypertension (as determined on at least two blood pressure determinations); obesity was present in 22, chronic obstructive pulmonary disease in eight, and renal insufficiency in 13; six of the 36 men had obstructive uropathy; five patients had a past history of malignant neoplasm. The prevalence rate of diabetes mellitus far exceeds that in the general population,'^ and is higher than in patients with atrioventricular block previously reported from this institution.' Five patients had a definite stroke prior to pacemaker implant. Two patients had carotid bruits. Organic brain syndrome, Parkinson's disease and previous saddle embolus were diagnosed in single patients.
Results
Between
Previous Status
Coexistent Disease Before Implant
There was a high prevalence of chronic diseases in this population. Twenty-four Had Cardiac Status Before Implant Sinus bradycardia alone, either in combination with congestive failure incompletely responsive to medical therapy (five patients) or with syncope historically without dpcumenta- tion of sinoatrial block (five patients), was seen in ten. Characteristically, rates under 50/min were seen and, in most cases, rates failed to exceed 70/min with moderate exercise. Sinoatrial block or arrgst" in combination with sinus bradycardia was seen in 30 patients; 19 patients were classified as having "bradycardia-tachycardia syndrome". Twelve of these had atrial fibrillation or flutter, two had multifocal atrial tachycardia and five had atrial tachycardia. There was no correlation between the etiology of heart disease and the type of arrhythmia seen (Table II) . Ventricular premature beats were also common. Twelve patients had unifocal, and two had multifocal PVCs during their pre-implant evaluation; seven patierits had one or more episodes of ventricular tachycardia, and one patient had been resuscitated from ventricular fibrillation prior to pacemaker implant. Left bundle branch block was present in four, isolated right bundle branch block in two, left anterior fascicular block in two, right bundle branch block with left anterior fascicular block in three, alternating right and left bundle branch block in one, and prolonged PR interval in 15.
Sixteen patients had congestive heart failure in combination with their arrhythmia. Eleven patients had mild, and eleven had marked cardiomegaly by chest roentgenogram. There was a wide variability in the duration of sympr toms among all patients, regardless of etiology of heart disease. Twenty-four patients had symptoms of heart disease or arrhythmias for less than one year, but 18 patients had symptoms for over five years. The median duration of symptoms for patients in the idiopathic group was 12 months (range: < 1 month -18 years), while those with ischemic heart disease had a median duration of symptoms of 54 months. Forty-six of the 59 patients had presyncope or syncope; 23 described these symptoms for over 12 months; nine of these had described such episodes for eight years or more.
Course Following Pacemaker Implant
Mortality
Overall survival and the correlation between survival and underlying cardiac disease is shown in Figure 1 . Eighteen patients have died in the follow-up period. The six-month, oneyear and five-year survival was 91%, 85.5%, and 73.1%, respectively. Early deaths were usually cardiac, while late deaths were usually due to non-cardiac causes. Mortality was significantly higher in those with ischemic heart disease (p < 0.02) (Fig. 1) , and tended to be higher in those with congestive heart failure prior to implant (p = 0.07). Mortality was very low in those with sinus bradycardia alone (85.9% survival at three years), but significantly greater in those with sinoatrial arrest or bradycardia-tachycardia syndrome (64.8% and 75.6%, respecti,vely) (p< .05) (Fig. 2) . There was a poorer correlation be- tween survival and age. The five-year survival for those less than 65 years old was 74%, and 637o for those over 65 (N,S,, p = 0.17), The mortality exceeded that of sex-and age-matched cohtrols from the general U,S, population.' Progressive and refractory congestive heart failure was a common cause of death; three of 18 deaths in this series were primarily attributed to heart failure (Table III) , Six additional patients died of definite (unequivocal ECG, enzyme or autopsy data) or probable (characteristic history but no autopsy confirmation) acute myocardial infarction. Two patients with ischemic heart disease died of an acute myocardial infarction and shock within five days after the initial transvenous pacemaker implantation. Three patients died suddenly, two of whom had ventricular tachycardia before implant. Therefore, at least 12 of the 18 deaths were due to cardiac events. In three patients, insufficient data was available to determine the immediate cause of death, and two patients died of pulmonary causes. Nine deaths occurred in the hospital and three in convalescent facilities; eight patients were autopsied. In no patient did pacemaker malfunction contribute to death.
Morbidity
Although one of the recognized indications for permanent pacemaker implantation is to improve symptoms of congestive failure in patients with slow heart rates, it was necessary to continue digitalis or diuretics during follow-up in all but one patient with heart failure before implant. However, symptoms generally improved and overall management was simplified in most after pacing; five additional pa- tiehts have required treatment for chronic congestive heart failure following pacemaker implantation; in at least three this appeared following a definite or probable myocardial infarction. One patient with mitral valve prolapse, sinus bradycardia, long QT syndrome, and v.entricular tachycardia has been resuscitated from ventricular fibrillation. In addition tb the major central nervous system events before implant, during follow-up two patients have had a complete stroke and three have had transient ischemic attacks; jDrogressive chronic brain syndrome occurred in two. Progressive and severe renal insufficiency was seen in three, and four patients have had major pulmonary complications (either pulmonary insufficiency or pulmonary embolus) which resulted in death in two of these. One patient has had a new malignancy.
Arrhythmias in the Late FoJJow-up Period
In addition to the resuscitated patient, 16 of the patients have had elective 24-hour ambulatory monitoring on a random basis 1 to 108 months following initial pacemaker implant. Only two had no PVCs; eight had < 1 PVC/1000 normal or paced beats, but four (25%) had 1 to 10 PCVs and three (18%) have > 30 PVCs/lOOO normal beats. Ten of the 14 patients with PVCs have multiformed PVCs, and three have couplets; two have had sustained ventricular tachycardia noted during routine monitoring, which has resulted in the addition of antiarrhythmic agents to their present drug program. Both of these latter patients are in the cardiomyopathy group. There was no correlation between the severity of the ventricular arrhythmias noted and the etiology of the underlying heart disease.
In two patients in this series, pacing was discontinued one and one-half and four years after implant without return of symptoms. One of the patients with bradycardia-tachycardia syndrome refused pacemaker replacement. Four years later, he was asymptoitiatic despite the fact that his pacemaker had ceased functioning. Mild sinus bradycardia persists. Pacing was cautiously discontinued 18 months following implant in a young woman with spinal cord trauma and sinoatrial block whose initial pacemaker required removal because of pulse generator erosion. Her bradyarrhythmia has not returned.
The long term follow-up of the pattern of supraventricular arrhythmias is summarized in Table IV . Seven of the 19 patients (37%) with bradycardia-tachycardia syndrome have converted to chronic atrial fibrillation during follow-up. Conversion occurred from 11 to 60 months after implant (mean: 38.6 months). No patient with isolated sinus bradycardia or sinoatrial arrest has developed chronic or recur- rent supraventricular arrhythmias during follow-up although the one patient with sinus bradycardia, mitral valve prolapse, and long QT syndrome has exercise-induced atrial fibrillation and atrial tachycardia, and two patients with sinoatrial arrest have had isolated episodes of atrial fibrillation. In two patients (3.8%), high grade AV block was documented at the time of pacemaker inhibition in the clinic within one year of initial implant.
Discussion
There is a wide variation in the reported mortality in patients with sinus node disease. In the series by Rokseth and Hatle,'^ Rubenstein et al, ' Conde et al,= and Aroesty et al,'« death was reported to be infrequent following pacemaker implant. Krishaswami and Geraci," and Wohl et al,'° however, have observed a significant mortality, especially within the first two years after pacemaker insertion, and similar results are seen in this study. In part, the reported differences in survival can be attributed to differences in patients selection. Conde et al,= for example, excluded all patients who had had an acute myocardial infarction within one year. Such patients had a poor prognosis in the present series. Others have included patients only in the bradycardia-tachycardia subgroup of this syndrome.'*'^'"'" Wohl et al" excluded those lost to follow-up, and Wan et aP° and Rubenstein et aP included many asymptomatic patients not permanently paced. The age group from which the patients are drawn may also play some role. The age of the group is slightly older than that reported by Radford and Julian,' but younger than others.Î t is quite clear from this series that significant mortality exists in this population, but that mortality, particularly early mortality, is highest in the ischemic heart disease subgroup. For example, six of the 19 patients with ischemic heart disease died within the first 12 months after pacemaker implant, while only two deaths occurred in the remaining 40 patients without ischemic heart disease. It should be noted, however, that those in the ischemic heart disease subgroup were also slightly older than the patients with idiopathic, valvular, or primary myocardial disease, and had a higher prevalence of diabetes mellitus, hypertension, chronic lung disease, and congestive heart failure. While none of these factors alone could be demonstrated to influence mortality in a statistically significant way in this small study group, their combined influence may have contributed to overall mortality. The pattern of mortality was similar to that reported by Fruehan et al. '' Persistent ventricular arrhythmias during follow-up were common, but their presence did not appear to correlate with underlying cardiac disease. Of particular interest was the high rate of conversion of patients with symptomatic supraventricular arrhythmias prior to implant to chronic atriai fibrillation during the followup period. In fact, no patient with only sinus bradycardia or periods of sinoatrial arrest without supraventricular arrhythmias has progressed to chronic atriai fibrillation during follow-up, although two have bad transient atriai fibrillation. Amikam and Riss" reported tbat seven of 25 patients with sick sinus syndrome developed cbronic atriai fibrillation, but tbis was noted in botb tbe bradyarrbythmia and tbe bradycardia-tacbycardia subgroups. Vera et al" bave previously reported tbat 11 of 40 patients in theiriseries bad done likewise.lt is apparent tbat tbe development of cbronic atriai fibrillation is a common late development in patients witb sinus node disease. It is uncertain wbetber patients in tbis subgroup will remain in atriai fibrillation indefinitely or require pacing at all at tbis time; in no sucb patient in tbis series bas pacing been discontinued.
Pacing bas been discontinued indefinitely, bowever, in two patients wben tbe opportunity arose to re-evaluate tbem witbout a permanent pacemaker-once because of lack of patient cooperation in follow-up, and once because late infection dictated removal of tbe system and a period of observation. Sucb opportunities are uncommon, and periodic reassessment of tbe remaining patients in tbis series at tbe time of pacemaker inbibition in tbe clinic setting or at tbe time of pulse generator replacement would indicate tbat otber tban tbose wbo bave converted to atriai fibrillation, tbere are few wbo would be likely to bave bad resolution of tbe bradyarrbytbmia.
Tbe patient witb marked sinus bradycardia alone represents a difficult problem. Wben overt syncope bistorically accompanies tbe bradyarrbythmia, repeated ambulatory monitoring or electropbysiologic provocative studies may elucidate a possible mecbanism for tbe syncope. Despite tbese efforts, five of tbe ten patients in tbis series witb sinus bradycardia alone and syncope bad no sustained asystolic event documented. Four bave bad resolution of syncopal episodes. One bas persistent ventricular arrbytbmias requiring supression. Tbe otber five bad overt congestive beart failure or severe activity restriction and sinus bradycardia. One died suddenly shortly following implant. One is essentially asymptomatic, altbougb tbe need for occasional diuretics and pronounced cardiomegaly persists. Tbe remaining tbree require continuous treatment for beart failure wbicb is markedly improved since implant. It is obvious tbat tbis is not a bomogeneous group of patients, but in all, management was simplified and symptoms improved following pacemaker implant.
Altbougb intraventricular conduction disturbances are common prior to implant," in only two patients bas atrioventricular block been noted during follow-up. One of tbese bad a prolonged PR interval prior to implant. Previous studies bave indicated tbat progression to atrioventricular block was uncommon in patients witb sinus node disease paced from tbe coronary sinus. Moss et al" reported tbat only one of 27 patients paced for sinus node disease developed atrioventricular block during follow-up, and tbis series is in agreement witb tbat observation. Atriai or coronary sinus pacing, therefore, would appear to be a logical, and possibly beneficial, metbod of long-term pacing for tbe group of patients witb congestive beart failure in combination witb sinus bradycardia or sinoatrial arrest. Tbere appears to be only a small probability tbat conversion to atrioventricular sequential or ventricular pacing would be required later in tbeir course.
Tbe survival after pacemaker insertion for sinus node disease is similar to tbe survival of patients paced for atrioventricular block previously reported from tbis institution during tbe same time period.' From tbis retrospective analysis of patients witb sinus node disease, tbe presence of iscbemic beart disease identifies a patient witb a poor prognosis. A more favorable, but bardly benign long-term outlook, exists for tbe symptomatic group witb beart disease of anotber etiology.
Progression of ventricular dysfunction, worsening underlying ventricular arrbytbmias leading to sudden deatb, and a significant risk of cerebral emboli also appear common in tbis pa-tient population and contribute to morbidity and mortality.^' The result of this analysis suggests that long-term survival following pacemaker implantation in patients with symptomatic sinus node disease is correlated with a number of variables, including (1] the etiology of the underlying heart disease, (2) associated congestive heart failure, (3) age, and (4) the specific arrhythmias demonstrated prior to implant.
